Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 known ✓ | P00918 | 1/20 | 0.36 |
| ▸ | ITGB3 known ✓ | P05106 | 1/20 | 0.34 |
| ▸ | ITGA2B known ✓ | P08514 | 1/20 | 0.34 |
| ▸ | KLK7 | P49862 | 1/20 | 0.37 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.37 |
| ▸ | SIRT2 | Q8IXJ6 | 5/20 | 0.37 |
| ▸ | SIRT1 | Q96EB6 | 4/20 | 0.37 |
| ▸ | SIRT3 | Q9NTG7 | 4/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | TGM2 | P21980 | 6/20 | 0.36 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.35 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.35 |
| ▸ | CPB1 | P15086 | 1/20 | 0.35 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.35 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2107172 | 0.99 | KLK7 (0.38) | KLK7KLK5SIRT2SIRT1SIRT3 | |
| SCHEMBL2110237 | 0.90 | KLK7 (0.42) | KLK7KLK5CA1CA2TGM2 | |
| Hydrochloric Acid SCHEMBL2107171 | 0.90 | MAOA (0.40) | KLK7KLK5SIRT2SIRT1SIRT3 | |
| SCHEMBL2108865 | 0.89 | MAOA (0.41) | KLK7KLK5SIRT2SIRT1SIRT3 | |
| SCHEMBL2109811 | 0.83 | HTR6 (0.33) | — | |
| SCHEMBL2110170 | 0.80 | KLK7 (0.42) | KLK7KLK5TGM2ITGB3ITGA2B | |
| Hydrochloric Acid SCHEMBL2107174 | 0.80 | — | — | |
| SCHEMBL2111802 | 0.76 | DPP4 (0.38) | — | |
| SCHEMBL701776 | 0.74 | SMN1; SMN2 (0.37) | — | |
| SCHEMBL2109045 | 0.73 | RORC (0.35) | DPP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150336992-A1 | OXAZOLIDINONE-QUINOLONE HYBRID ANTIBIOTICS | MORPHOCHEM AG FÜR KOMBINATORISCHE CHEMIE (DE) | 2015-11-26 | — | — | US | disclosed |
| US-9133213-B2 | Oxazolidinone-quinolone hybrid antibiotics | Morphochem Aktiengesellschaft für kombinatorische Chemie (DE) | 2015-09-15 | — | — | US | disclosed |
| EP-1709044-B2 | OXAZOLIDINONE-QUINOLONE HYBRID ANTIBIOTICS | MORPHOCHEM AG KOMB CHEMIE (DE) | 2013-11-20 | — | — | EP | disclosed |
| US-20130296275-A1 | OXAZOLIDINONE-QUINOLONE HYBRID ANTIBIOTICS | MORPHOCHEM AG KOMB CHEMIE (DE) | 2013-11-07 | — | — | US | disclosed |
| US-8513231-B2 | Use of oxazolidinone-quinoline hybrid antibiotics for the treatment of anthrax and other infections | Morphochem Aktiengesellschaft fü Kombinatorische Chemie (DE) | 2013-08-20 | — | — | US | disclosed |
| US-8501774-B2 | Oxazolidinone-quinolone hybrid antibiotics | Morphochem Aktiengesellschaft für kombinatorische Chemie (DE) | 2013-08-06 | — | — | US | disclosed |
| US-20120322766-A1 | USE OF OXAZOLIDINONE-QUINOLINE HYBRID ANTIBIOTICS FOR THE TREATMENT OF ANTHRAX AND OTHER INFECTIONS | MORPHOCHEM AKTIENGESELLSCHAFT FUER KOMBINATORISCHE CHEMIE (DE) | 2012-12-20 | — | — | US | disclosed |
| US-8268812-B2 | Use of oxazolidinone-quinoline hybrid antibiotics for the treatment of anthrax and other infections | Morphochem Aktiengesellschaft fül Kombinatorische Chemie (DE) | 2012-09-18 | — | — | US | disclosed |
| US-20120142635-A1 | OXAZOLIDINONE-QUINOLONE HYBRID ANTIBIOTICS | MORPHOCHEM AKTIENGESELLSCHAFT FUR KOMBINATORISCHE CHEMIE (DE) | 2012-06-07 | — | — | US | disclosed |
| US-20120135961-A1 | USE OF OXAZOLIDINONE-QUINOLINE HYBRID ANTIBIOTICS FOR THE TREATMENT OF ANTHRAX AND OTHER INFECTIONS | MORPHOCHEM AKTIENGESELLSCHAFT FUR KOMBINATORISCHE CHEMIE (DE) | 2012-05-31 | — | — | US | disclosed |
| US-8158797-B2 | Oxazolidinone-quinolone hybrid antibiotics | MORPHOCHEM AKTIENGESELLSCHAFT FUR KOMBINATORISCHE CHEMIE (DE) | 2012-04-17 | — | — | US | disclosed |
| EP-1709044-B1 | OXAZOLIDINONE-QUINOLONE HYBRID ANTIBIOTICS | MORPHOCHEM AG KOMB CHEMIE (DE) | 2008-07-16 | — | — | EP | disclosed |
| EP-1620098-B1 | USE OF OXAZOLIDINONE-QUINOLINE HYBRID ANTIBIOTICS FOR THE TREATMENT OF ANTHRAX AND OTHER INFECTIONS | MORPHOCHEM AG KOMB CHEMIE (DE) | 2008-06-11 | — | — | EP | disclosed |
| US-20080027040-A1 | Oxazolidinone-Quinolone Hybrid Antibiotics | MORPHOCHEM AKTIENGESELLSCHAFT FUR KOMBINATORISCHE (DE) | 2008-01-31 | — | — | US | disclosed |
| US-20070155714-A1 | Use of oxazolidinone-quinoline hybrid antibiotics for the treatment of anthrax and other infections | MORPHOCHEM AKTIENGESELLSCHAFT FUR KOMBINATORISCHE CHEMIE (DE) | 2007-07-05 | — | — | US | disclosed |
| EP-1620098-A1 | USE OF OXAZOLIDINONE-QUINOLINE HYBRID ANTIBIOTICS FOR THE TREATMENT OF ANTHRAX AND OTHER INFECTIONS | Morphochem Aktiengesellschaft Für Kombinatorische Chemie (DE) | 2006-02-01 | — | — | EP | disclosed |
| WO-2004096221-A1 | USE OF OXAZOLIDINONE-QUINOLINE HYBRID ANTIBIOTICS FOR THE TREATMENT OF ANTHRAX AND OTHER INFECTIONS | Morphochem Aktiengesellschaft für kombinatorische Chemie (DE) | 2004-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120135961-A1 | USE OF OXAZOLIDINONE-QUINOLINE HYBRID ANTIBIOTICS FOR THE TREATMENT OF ANTHRAX AND OTHER INFECTIONS | OXA1L, ANTXR2, AAAS | CA2 2426/4885ITGB3 4449/4885ITGA2B 4220/4885 |
| US-20150336992-A1 | OXAZOLIDINONE-QUINOLONE HYBRID ANTIBIOTICS | OXA1L, TOP1, TOP2A | CA2 3803/4885ITGB3 4087/4885ITGA2B 4020/4885 |
| US-20120322766-A1 | USE OF OXAZOLIDINONE-QUINOLINE HYBRID ANTIBIOTICS FOR THE TREATMENT OF ANTHRAX AND OTHER INFECTIONS | OXA1L, ANTXR2, AAAS | CA2 2426/4885ITGB3 4449/4885ITGA2B 4220/4885 |
| US-20070155714-A1 | Use of oxazolidinone-quinoline hybrid antibiotics for the treatment of anthrax and other infections | OXA1L, ANTXR2, AAAS | CA2 2426/4885ITGB3 4449/4885ITGA2B 4220/4885 |
| US-20120142635-A1 | OXAZOLIDINONE-QUINOLONE HYBRID ANTIBIOTICS | OXA1L, TOP1, TOP2A | CA2 3803/4885ITGB3 4087/4885ITGA2B 4020/4885 |
| US-20080027040-A1 | Oxazolidinone-Quinolone Hybrid Antibiotics | OXA1L, TOP1, TOP2A | CA2 3803/4885ITGB3 4087/4885ITGA2B 4020/4885 |
| US-20130296275-A1 | OXAZOLIDINONE-QUINOLONE HYBRID ANTIBIOTICS | OXA1L, TOP1, TOP2A | CA2 3803/4885ITGB3 4087/4885ITGA2B 4020/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.